Analyst Scoreboard: 4 Ratings For Crinetics Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Crinetics Pharmaceuticals (NASDAQ:CRNX) received 4 analyst ratings in the last quarter, with an average 12-month price target of $44.25, down from the previous $52.00. Ratings include 1 bullish and 3 overweight, with price targets ranging from $35.00 to $50.00. The company's financial health shows challenges with a revenue decline of -24.45%, a net margin of -16606.36%, and ROE of -14.33%. Despite this, it maintains a low debt-to-equity ratio of 0.1.
December 19, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Crinetics Pharmaceuticals has a mixed outlook with 1 bullish and 3 overweight ratings, and a reduced average price target of $44.25, indicating potential pressure on the stock price.
The reduction in the average price target from $52.00 to $44.25, along with significant financial challenges such as a sharp decline in revenue and negative profitability indicators, could lead to bearish sentiment in the short term. However, the company's low debt-to-equity ratio may provide some support. The ratings are directly related to CRNX and are critical for investors, hence the high relevance and importance. The confidence score reflects the clear data provided by the analysts' ratings and the company's financials.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100